Propionic Acid

Propionic Acid

SCHEMBL577043

CCC(=O)O.CCC(=O)O.OCC#CCO

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 2/20 0.62
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
TDP1 Q9NUW8 5/20 0.37
ALDH1A1 P00352 3/20 0.37
PTPN7 P35236 5/20 0.34
HMGCR P04035 3/20 0.34
AKR1B1 P15121 1/20 0.33
MMP2 P08253 1/20 0.32
MMP12 P39900 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
KDM4E B2RXH2 1/20 0.32
USP2 O75604 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
ALOX12 P18054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL2942829 0.88 FFAR3 (0.56) FFAR3HDAC3HDAC1HDAC2HDAC8
Propionic Acid SCHEMBL2168558 0.87 FFAR3 (0.48) FFAR3HDAC3HDAC1HDAC2HDAC8
Propionic Acid SCHEMBL3919152 0.83
Propionic Acid SCHEMBL7700842 0.83 FFAR3 (0.91) FFAR3HDAC3HDAC1HDAC2HDAC8
Propionic Acid SCHEMBL139572 0.83
Butyric Acid SCHEMBL8204914 0.80 FFAR3 (0.68) FFAR3HDAC3HDAC1HDAC2HDAC8
Acetic Acid SCHEMBL2166947 0.80 FFAR3 (0.50) FFAR3TDP1ALDH1A1MMP2MMP12
Propionic Acid SCHEMBL30292602 0.79 FFAR3 (0.83) FFAR3HDAC3HDAC1HDAC2HDAC8
Propionic Acid SCHEMBL29226970 0.79 FFAR3 (0.83) FFAR3HDAC3HDAC1HDAC2HDAC8
Propionic Acid SCHEMBL27700627 0.79 FFAR3 (0.83) FFAR3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6479191-B1 COMPRISING A NON-AQUEOUS SOLVENT, AN ELECTROLYTE SALT DISSOLVED THEREIN AND AT LEAST ONE ALKYNE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2002-11-12 US claimed
US-6156692-A Ruthenium-containing catalyst composition for olefin metathesis BP AMOCO CORPORATION (US) 2000-12-05 US claimed
US-12620622-B2 Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same DAIKIN INDUSTRIES, LTD. (JP) 2026-05-05 US disclosed
US-20250260063-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY DAIKIN INDUSTRIES, LTD. (JP) 2025-08-14 US disclosed
EP-3780232-B1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE DAIKIN IND LTD (JP) 2025-07-30 EP disclosed
US-20250233206-A1 NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2025-07-17 US disclosed
US-20250174720-A1 ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2025-05-29 US disclosed
US-12315883-B2 Non-aqueous electrolyte solution and non-aqueous electrolyte secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2025-05-27 US disclosed
US-12315885-B2 Electrolytic solution, electrochemical device, lithium-ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2025-05-27 US disclosed
EP-4553918-A1 NEGATIVE ELECTRODE, BATTERY, AND METHOD FOR COVERING BATTERY MATERIAL DAIKIN INDUSTRIES, LTD. (JP) 2025-05-14 EP disclosed
EP-4553940-A1 SECONDARY BATTERY DAIKIN INDUSTRIES, LTD. (JP) 2025-05-14 EP disclosed
US-6159890-A Ruthenium-containing catalyst system for olefin metathesis BP AMOCO CORPORATION (US) 2000-12-12 US disclosed
US-6156692-A Ruthenium-containing catalyst composition for olefin metathesis BP AMOCO CORPORATION (US) 2000-12-05 US disclosed
US-6143851-A Process for preparation of addition products of difunctional telechelic polyolefins from cyclic olefins by olefin metathesis reaction BP AMOCO CORPORATION (US) 2000-11-07 US disclosed
US-6060570-A Process for preparation of addition products of difunctional telechelic polyolefins from cyclic olefins by olefin metathesis reaction BP AMOCO CORPORATION (US) 2000-05-09 US disclosed
WO-1999022866-A1 A RUTHENIUM-CONTAINING CATALYST SYSTEM FOR OLEFIN METATHESIS BP AMOCO CORPORATION (US) 1999-05-14 WO disclosed
EP-0857183-A1 PROCESS FOR PREPARATION OF ADDITION PRODUCTS OF DIFUNCTIONAL TELECHELIC POLYOLEFINS FROM CYCLIC OLEFINS BY OLEFIN METATHESIS REACTION AMOCO CORPORATION (US) 1998-08-12 EP disclosed
EP-0841988-A1 A RUTHENIUM-BASED CATALYST SYSTEM FOR OLEFIN METATHESIS AMOCO CORPORATION (US) 1998-05-20 EP disclosed
WO-1998006771-A1 PROCESS FOR PREPARATION OF ADDITION PRODUCTS OF DIFUNCTIONAL TELECHELIC POLYOLEFINS FROM CYCLIC OLEFINS BY OLEFIN METATHESIS REACTION AMOCO CORPORATION (US) 1998-02-19 WO disclosed
WO-1997040934-A1 A RUTHENIUM-BASED CATALYST SYSTEM FOR OLEFIN METATHESIS AMOCO CORPORATION (US) 1997-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250174720-A1 ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE HCN2, HCN1, HCN3 FFAR3 1500/4885HDAC3 1627/4885HDAC1 543/4885
US-12620622-B2 Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same ASH2L, OLA1, ODC1 FFAR3 3531/4885HDAC3 146/4885HDAC1 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.